Search Results - "BUNIVA, T"

Relationship between CA 15-3 serum levels and disease extent in predicting overall survival of breast cancer patients with newly diagnosed metastatic disease by TAMPELLINI, M, BERRUTI, A, MORO, G, DELTETTO, F, DOGLIOTTI, L, GERBINO, A, BUNIVA, T, TORTA, M, GORZEGNO, G, FAGGIUOLO, R, CANNONE, R, FARRIS, A, DESTEFANIS, M

“…In order to study the relationship between circulating levels of CA 15-3 and the disease extent in predicting survival, we prospectively followed 312 breast…”
Get full text

Prognostic value in predicting overall survival of two mucinous markers: CA 15-3 and CA 125 in breast cancer patients at first relapse of disease by Berruti, A, Tampellini, M, Torta, M, Buniva, T, Gorzegno, G, Dogliotti, L

“…The role of circulating tumour markers in providing prognostic information has been scarcely studied. We evaluated the prognostic significance of two mucinous…”
Get more information

Lonidamine significantly increases the activity of epirubicin in patients with advanced breast cancer: results from a multicenter prospective randomized trial by Dogliotti, L, Berruti, A, Buniva, T, Zola, P, Baù, M G, Farris, A, Sarobba, M G, Bottini, A, Alquati, P, Deltetto, F, Gosso, P, Monzeglio, C, Moro, G, Sussio, M, Perroni, D

“…Some evidence in vitro and in vivo shows that lonidamine (LND) can positively modulate the activity of doxorubicin and epirubicin (EPI). On this basis, a…”
Get more information

Cisplatin, epirubicin, and lonidamine combination regimen as first-line chemotherapy for metastatic breast cancer : a pilot study by DOGLIOTTI, L, DANESE, S, PORCILE, G, BERRUTI, A, ZOLA, P, BUNIVA, T, BOTTINI, A, RICHIARDI, G, MORO, G, FARRIS, A, BAU, M. G

“…We assessed the activity and tolerability of a cisplatin, epirubicin, and lonidamine combination regimen as first-line chemotherapy in 28 advanced breast…”
Get full text

Prognostic factors in metastatic breast cancer patients obtaining objective response or disease stabilization after first-line chemotherapy with epirubicin. Evidence for a positive effect of maintenance hormonal therapy on overall survival by Berruti, A, Zola, P, Buniva, T, Baù, M G, Farris, A, Sarobba, M G, Bottini, A, Tampellini, M, Durando, A, Destefanis, M, Monzeglio, C, Moro, G, Sussio, M, Perroni, D, Dogliotti, L

“…Randomized trials suggest that the outcome of metastatic breast cancer (BC) patients is not affected by the currently available therapies. Although response…”
Get more information

Melatonin and human cancer by Dogliotti, L, Berruti, A, Buniva, T, Torta, M, Bottini, A, Tampellini, M, Terzolo, M, Faggiuolo, R, Angeli, A

“…A number of studies performed in vitro and on experimental animals supported the view that pineal gland inhibits neoplastic growth. Data in humans are scanty…”
Get more information

Exogenous melatonin enhances the TRH-induced prolactin release in normally cycling women: a sex-specific effect by Terzolo, M, Piovesan, A, Osella, G, Torta, M, Buniva, T, Paccotti, P, Wierdis, T, Angeli, A

“…The aim of the present study was to analyze the effects of exogenous melatonin (MT) upon pituitary and adrenal responsiveness to releasing hormones in…”
Get more information

Circadian profile of serum melatonin in Cushing's disease and acromegaly by Piovesan, A, Terzolo, M, Borretta, G, Torta, M, Buniva, T, Osella, G, Paccotti, P, Angeli, A

“…We evaluated the circadian profiles of serum melatonin (MT) and cortisol in 6 patients with Cushing's disease while those of serum MT and GH were evaluated in…”
Get more information

Transferability to clinical practice of the results of controlled clinical trials: The case of antiemetic prophylactic treatment for cancer chemotherapy-induced nausea and vomiting

“…Background There is convincing evidence from randomized clinical trials that the use of 5-HT3 antagonists has brought about a substantial improvement in the…”
Get full text

681 Prognostic value of CA 15-3 in advanced breast cancer (BC) patients: Relationship with the disease extent (DE) by Tampellini, M., Berruti, A., Gerbino, A., Buniva, T., Torta, M., Faggiuolo, R., Gorzegno, G., Dogliotti, L.

“…The prognostic value of CA 15-3 in BC patients at first relapse of disease may be ascribed to the correlation of marker levels with DE or with the tumor…”
Get full text

Is an antiemetic prophylactic treatment needed for patients submitted to consecutive days of 5-fluorouracil? An observational study by De Angelis, Verena, Roila, Fausto, Tonato, Maurizio, Ballatori, Enzo, Del Favero, Albano

“…The necessity of an antiemetic prophylaxis in patients treated with chemotherapy of low emetogenic potential, such as 5-fluorouracil +/- folinic acid…”
Get full text

Randomized comparison of goserelin acetate versus mitomycin C plus goserelin acetate in previously untreated prostate cancer patients with bone metastases by Fontana, D, Bertetto, O, Fasolis, G, Berruti, A, Tarabuzzi, R, Pagani, G, Buniva, T, Zolfanelli, R, Pallotti, S, Frezzotti, L, Bumma, C, Rossetti, S R, Dogliotti, L

“…In a prospective trial conducted by the Gruppo Onco Urologico Piemontese, newly diagnosed prostate cancer patients with bone metastases were randomized to…”
Get more information